

Ricky w Johnstone

List of Publications by Citations

Source: <https://exaly.com/author-pdf/982939/ricky-w-johnstone-publications-by-citations.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

251
papers

25,431
citations

78
h-index

156
g-index

270
ext. papers

28,285
ext. citations

11.3
avg, IF

7.21
L-index

#	Paper	IF	Citations
251	Anticancer activities of histone deacetylase inhibitors. <i>Nature Reviews Drug Discovery</i> , 2006 , 5, 769-84	64.1	2286
250	Apoptosis: a link between cancer genetics and chemotherapy. <i>Cell</i> , 2002 , 108, 153-64	56.2	1883
249	Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. <i>Nature Reviews Drug Discovery</i> , 2002 , 1, 287-99	64.1	1177
248	Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. <i>Nature Reviews Drug Discovery</i> , 2014 , 13, 673-91	64.1	1028
247	New and emerging HDAC inhibitors for cancer treatment. <i>Journal of Clinical Investigation</i> , 2014 , 124, 30-9	15.9	936
246	The TRAIL apoptotic pathway in cancer onset, progression and therapy. <i>Nature Reviews Cancer</i> , 2008 , 8, 782-98	31.3	690
245	Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007 , 104, 19512-7	11.5	569
244	Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005 , 102, 3697-702	11.5	451
243	The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004 , 101, 10000-0	11.5	430
242	Histone deacetylase inhibitors in cancer therapy: is transcription the primary target?. <i>Cancer Cell</i> , 2003 , 4, 13-8	24.3	425
241	Epigenetics in cancer: targeting chromatin modifications. <i>Molecular Cancer Therapeutics</i> , 2009 , 8, 1409-20.1	20.1	384
240	Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53. <i>Cancer Cell</i> , 2012 , 22, 51-65	24.3	368
239	Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy. <i>PLoS Pathogens</i> , 2014 , 10, e1004473	7.6	358
238	Structures of the HIN domain:DNA complexes reveal ligand binding and activation mechanisms of the AIM2 inflammasome and IFI16 receptor. <i>Immunity</i> , 2012 , 36, 561-71	32.3	352
237	BET inhibitor resistance emerges from leukaemia stem cells. <i>Nature</i> , 2015 , 525, 538-42	50.4	345
236	Initiation of apoptosis by granzyme B requires direct cleavage of bid, but not direct granzyme B-mediated caspase activation. <i>Journal of Experimental Medicine</i> , 2000 , 192, 1403-14	16.6	300
235	The drug efflux protein, P-glycoprotein, additionally protects drug-resistant tumor cells from multiple forms of caspase-dependent apoptosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1998 , 95, 7024-9	11.5	299

234	Constitutive type I interferon modulates homeostatic balance through tonic signaling. <i>Immunity</i> , 2012 , 36, 166-74	32.3	291
233	P-Glycoprotein Protects Leukemia Cells Against Caspase-Dependent, but not Caspase-Independent, Cell Death. <i>Blood</i> , 1999 , 93, 1075-1085	2.2	273
232	Multiple physiological functions for multidrug transporter P-glycoprotein?. <i>Trends in Biochemical Sciences</i> , 2000 , 25, 1-6	10.3	270
231	Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma. <i>Clinical Cancer Research</i> , 2008 , 14, 4500-10	12.9	257
230	IFNgamma signaling-does it mean JAK-STAT?. <i>Cytokine and Growth Factor Reviews</i> , 2008 , 19, 383-94	17.9	232
229	A novel repressor, par-4, modulates transcription and growth suppression functions of the WilmsO tumor suppressor WT1. <i>Molecular and Cellular Biology</i> , 1996 , 16, 6945-56	4.8	232
228	Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia. <i>Nature Communications</i> , 2018 , 9, 5341	17.4	227
227	Radiotherapy increases the permissiveness of established mammary tumors to rejection by immunomodulatory antibodies. <i>Cancer Research</i> , 2012 , 72, 3163-74	10.1	208
226	UV-Associated Mutations Underlie the Etiology of MCV-Negative Merkel Cell Carcinomas. <i>Cancer Research</i> , 2015 , 75, 5228-34	10.1	196
225	Cloning a novel member of the human interferon-inducible gene family associated with control of tumorigenicity in a model of human melanoma. <i>Oncogene</i> , 1997 , 15, 453-7	9.2	196
224	Rational combinations using HDAC inhibitors. <i>Clinical Cancer Research</i> , 2009 , 15, 3970-7	12.9	195
223	Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007 , 104, 8071-6	11.5	185
222	Enhancing the apoptotic and therapeutic effects of HDAC inhibitors. <i>Cancer Letters</i> , 2009 , 280, 125-33	9.9	184
221	Expression and function of the leucine zipper protein Par-4 in apoptosis. <i>Molecular and Cellular Biology</i> , 1997 , 17, 3823-32	4.8	183
220	Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy. <i>Journal of Clinical Investigation</i> , 2017 , 127, 929-941	15.9	183
219	Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis. <i>Cancer Discovery</i> , 2014 , 4, 423-33	24.4	180
218	Histone deacetylase inhibitors in cancer therapy. <i>Expert Opinion on Investigational Drugs</i> , 2007 , 16, 659-78	8.9	178
217	BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1. <i>Cell Reports</i> , 2017 , 18, 2162-2174	10.6	170

216	The BH3-only protein bid is dispensable for DNA damage- and replicative stress-induced apoptosis or cell-cycle arrest. <i>Cell</i> , 2007 , 129, 423-33	56.2	170
215	Epigenetic changes to the MDR1 locus in response to chemotherapeutic drugs. <i>Oncogene</i> , 2005 , 24, 8061-75	9.75	169
214	Novel mechanisms of apoptosis induced by histone deacetylase inhibitors. <i>Cancer Research</i> , 2003 , 63, 4460-71	10.1	160
213	An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice. <i>Journal of Clinical Investigation</i> , 2012 , 122, 553-7	15.9	144
212	Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy. <i>Blood</i> , 2012 , 120, 376-85	2.2	143
211	The HIN-200 family: more than interferon-inducible genes?. <i>Experimental Cell Research</i> , 2005 , 308, 1-17	4.2	132
210	HDAC inhibitors induce tumor-cell-selective pro-apoptotic transcriptional responses. <i>Cell Death and Disease</i> , 2013 , 4, e519	9.8	126
209	T-cell acute leukaemia exhibits dynamic interactions with bone marrow microenvironments. <i>Nature</i> , 2016 , 538, 518-522	50.4	122
208	Tumor immune evasion arises through loss of TNF sensitivity. <i>Science Immunology</i> , 2018 , 3,	28	119
207	Deciphering the molecular and biologic processes that mediate histone deacetylase inhibitor-induced thrombocytopenia. <i>Blood</i> , 2011 , 117, 3658-68	2.2	118
206	Histone deacetylase inhibitors specifically kill nonproliferating tumour cells. <i>Oncogene</i> , 2004 , 23, 6693-701	11	118
205	Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008 , 105, 11317-22	11.5	114
204	The caspase-8 inhibitor emricasan combines with the SMAC mimetic birinapant to induce necroptosis and treat acute myeloid leukemia. <i>Science Translational Medicine</i> , 2016 , 8, 339ra69	17.5	111
203	Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors. <i>Future Oncology</i> , 2009 , 5, 601-12	3.6	111
202	Histone-Deacetylase Inhibitors for the Treatment of Cancer. <i>Cell Cycle</i> , 2004 , 3, 777-786	4.7	110
201	Functional crosstalk between type I and II interferon through the regulated expression of STAT1. <i>PLoS Biology</i> , 2010 , 8, e1000361	9.7	108
200	Efficacy of CHK inhibitors as single agents in MYC-driven lymphoma cells. <i>Oncogene</i> , 2012 , 31, 1661-72	9.2	106
199	Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect. <i>Investigational New Drugs</i> , 2010 , 28 Suppl 1, S3-20	4.3	106

198	AKT promotes rRNA synthesis and cooperates with c-MYC to stimulate ribosome biogenesis in cancer. <i>Science Signaling</i> , 2011 , 4, ra56	8.8	104
197	Inhibitors of histone acetyltransferases KAT6A/B induce senescence and arrest tumour growth. <i>Nature</i> , 2018 , 560, 253-257	50.4	103
196	Transcription and growth regulatory functions of the HIN-200 family of proteins. <i>Molecular and Cellular Biology</i> , 1999 , 19, 5833-8	4.8	103
195	A member of the Pyrin family, IFI16, is a novel BRCA1-associated protein involved in the p53-mediated apoptosis pathway. <i>Oncogene</i> , 2003 , 22, 8931-8	9.2	102
194	A central role for Bid in granzyme B-induced apoptosis. <i>Journal of Biological Chemistry</i> , 2005 , 280, 4476-82	8.4	101
193	The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efficacy. <i>Blood</i> , 2009 , 114, 380-93	2.2	100
192	A role for P-glycoprotein in regulating cell death. <i>Leukemia and Lymphoma</i> , 2000 , 38, 1-11	1.9	100
191	Combined targeting of JAK2 and Bcl-2/Bcl-xL to cure mutant JAK2-driven malignancies and overcome acquired resistance to JAK2 inhibitors. <i>Cell Reports</i> , 2013 , 5, 1047-59	10.6	98
190	An intact immune system is required for the anticancer activities of histone deacetylase inhibitors. <i>Cancer Research</i> , 2013 , 73, 7265-76	10.1	96
189	A dual role for Hdac1: oncosuppressor in tumorigenesis, oncogene in tumor maintenance. <i>Blood</i> , 2013 , 121, 3459-68	2.2	95
188	Human immunodeficiency virus type 1 Nef binds to tumor suppressor p53 and protects cells against p53-mediated apoptosis. <i>Journal of Virology</i> , 2002 , 76, 2692-702	6.6	95
187	Whole exome sequencing reveals activating JAK1 and STAT3 mutations in breast implant-associated anaplastic large cell lymphoma. <i>Haematologica</i> , 2016 , 101, e387-90	6.6	94
186	Asymmetric cell division of T cells upon antigen presentation uses multiple conserved mechanisms. <i>Journal of Immunology</i> , 2010 , 185, 367-75	5.3	94
185	Role of IFI 16, a member of the interferon-inducible p200-protein family, in prostate epithelial cellular senescence. <i>Oncogene</i> , 2003 , 22, 4831-40	9.2	94
184	CDK9 inhibition by dinaciclib potently suppresses Mcl-1 to induce durable apoptotic responses in aggressive MYC-driven B-cell lymphoma in vivo. <i>Leukemia</i> , 2015 , 29, 1437-41	10.7	90
183	Eradication of solid tumors using histone deacetylase inhibitors combined with immune-stimulating antibodies. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011 , 108, 4141-6	11.5	88
182	Functional interaction between p53 and the interferon-inducible nucleoprotein IFI 16. <i>Oncogene</i> , 2000 , 19, 6033-42	9.2	88
181	Mutational analysis of P-glycoprotein: suppression of caspase activation in the absence of ATP-dependent drug efflux. <i>Cell Death and Differentiation</i> , 2004 , 11, 1028-37	12.7	87

180	Intrinsic and extrinsic apoptotic pathway signaling as determinants of histone deacetylase inhibitor antitumor activity. <i>Advances in Cancer Research</i> , 2012 , 116, 165-97	5.9	84
179	Differentiation therapy for the treatment of t(8;21) acute myeloid leukemia using histone deacetylase inhibitors. <i>Blood</i> , 2014 , 123, 1341-52	2.2	82
178	Polymorphic expression of CD46 protein isoforms due to tissue-specific RNA splicing. <i>Molecular Immunology</i> , 1993 , 30, 1231-41	4.3	82
177	Identification and quantification of complement regulator CD46 on normal human tissues. <i>Immunology</i> , 1993 , 79, 341-7	7.8	81
176	Targeting the epigenetic regulation of antitumour immunity. <i>Nature Reviews Drug Discovery</i> , 2020 , 19, 776-800	64.1	81
175	How do tumor cells respond to HDAC inhibition?. <i>FEBS Journal</i> , 2016 , 283, 4032-4046	5.7	81
174	Oncogenes in cell survival and cell death. <i>Cold Spring Harbor Perspectives in Biology</i> , 2012 , 4,	10.2	79
173	Histone deacetylase inhibitors in lymphoma and solid malignancies. <i>Expert Review of Anticancer Therapy</i> , 2008 , 8, 413-32	3.5	78
172	HMBA induces activation of a caspase-independent cell death pathway to overcome P-glycoprotein-mediated multidrug resistance. <i>Blood</i> , 2000 , 95, 2378-2385	2.2	75
171	The CDK9 Inhibitor Dinaciclib Exerts Potent Apoptotic and Antitumor Effects in Preclinical Models of MLL-Rearranged Acute Myeloid Leukemia. <i>Cancer Research</i> , 2016 , 76, 1158-69	10.1	73
170	Combination Therapy Targeting Ribosome Biogenesis and mRNA Translation Synergistically Extends Survival in MYC-Driven Lymphoma. <i>Cancer Discovery</i> , 2016 , 6, 59-70	24.4	73
169	Filamin (280-kDa actin-binding protein) is a caspase substrate and is also cleaved directly by the cytotoxic T lymphocyte protease granzyme B during apoptosis. <i>Journal of Biological Chemistry</i> , 2000 , 275, 39262-6	5.4	73
168	Defining the target specificity of ABT-737 and synergistic antitumor activities in combination with histone deacetylase inhibitors. <i>Blood</i> , 2009 , 113, 1982-91	2.2	72
167	Dual-specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine Eradicate a Variety of Large Solid Tumors in an Immunocompetent, Self-antigen Setting. <i>Clinical Cancer Research</i> , 2017 , 23, 2478-2490	12.9	71
166	Targeting p38 or MK2 Enhances the Anti-Leukemic Activity of Smac-Mimetics. <i>Cancer Cell</i> , 2016 , 29, 145-58	5.3	71
165	P-glycoprotein inhibits caspase-8 activation but not formation of the death inducing signal complex (disc) following Fas ligation. <i>Cell Death and Differentiation</i> , 2002 , 9, 1266-72	12.7	71
164	From cancer immunosurveillance to cancer immunotherapy. <i>Immunological Reviews</i> , 2007 , 220, 82-101	11.3	70
163	Functional interdependence of BRD4 and DOT1L in MLL leukemia. <i>Nature Structural and Molecular Biology</i> , 2016 , 23, 673-81	17.6	69

162	A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma. <i>Blood</i> , 2011 , 118, 6274-83	2.2	69
161	Fas ligand-mediated immune surveillance by T cells is essential for the control of spontaneous B cell lymphomas. <i>Nature Medicine</i> , 2014 , 20, 283-90	50.5	68
160	In vivo activity of combined PI3K/mTOR and MEK inhibition in a Kras(G12D);Pten deletion mouse model of ovarian cancer. <i>Molecular Cancer Therapeutics</i> , 2011 , 10, 1440-9	6.1	66
159	Suberoylanilide hydroxamic acid (SAHA) overcomes multidrug resistance and induces cell death in P-glycoprotein-expressing cells. <i>International Journal of Cancer</i> , 2002 , 99, 292-8	7.5	65
158	Differential induction of apoptosis and senescence by the DNA methyltransferase inhibitors 5-azacytidine and 5-aza-2-deoxycytidine in solid tumor cells. <i>Molecular Cancer Therapeutics</i> , 2013 , 12, 2226-36	6.1	64
157	Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors. <i>European Journal of Cancer</i> , 2013 , 49, 3936-44	7.5	63
156	Identification, cloning, expression, and biochemical characterization of the testis-specific RNA polymerase II elongation factor ELL3. <i>Journal of Biological Chemistry</i> , 2000 , 275, 32052-6	5.4	62
155	Inhibition of RNA polymerase I transcription initiation by CX-5461 activates non-canonical ATM/ATR signaling. <i>Oncotarget</i> , 2016 , 7, 49800-49818	3.3	62
154	Thalidomide-analogue biology: immunological, molecular and epigenetic targets in cancer therapy. <i>Oncogene</i> , 2013 , 32, 4191-202	9.2	61
153	Inhibition of retinoblastoma protein degradation by interaction with the serpin plasminogen activator inhibitor 2 via a novel consensus motif. <i>Molecular and Cellular Biology</i> , 2003 , 23, 6520-32	4.8	61
152	Manipulation of B-cell responses with histone deacetylase inhibitors. <i>Nature Communications</i> , 2015 , 6, 6838	17.4	60
151	Socrates: identification of genomic rearrangements in tumour genomes by re-aligning soft clipped reads. <i>Bioinformatics</i> , 2014 , 30, 1064-1072	7.2	60
150	Characterisation of the novel apoptotic and therapeutic activities of the histone deacetylase inhibitor romidepsin. <i>Molecular Cancer Therapeutics</i> , 2008 , 7, 1066-79	6.1	58
149	The human interferon-inducible protein, IFI 16, is a repressor of transcription. <i>Journal of Biological Chemistry</i> , 1998 , 273, 17172-7	5.4	58
148	The anticancer effects of HDAC inhibitors require the immune system. <i>Onc Immunology</i> , 2014 , 3, e27414	4.2	56
147	A chemical probe toolbox for dissecting the cancer epigenome. <i>Nature Reviews Cancer</i> , 2017 , 17, 160-183	31.3	54
146	Combined inhibition of PI3K-related DNA damage response kinases and mTORC1 induces apoptosis in MYC-driven B-cell lymphomas. <i>Blood</i> , 2013 , 121, 2964-74	2.2	54
145	Ciao 1 is a novel WD40 protein that interacts with the tumor suppressor protein WT1. <i>Journal of Biological Chemistry</i> , 1998 , 273, 10880-7	5.4	54

144	NKT cell adjuvant-based tumor vaccine for treatment of myc oncogene-driven mouse B-cell lymphoma. <i>Blood</i> , 2012 , 120, 3019-29	2.2	53
143	Expression of IFI 16 in epithelial cells and lymphoid tissues. <i>Histochemistry and Cell Biology</i> , 2003 , 119, 45-54	2.4	53
142	The mTORC1 inhibitor everolimus prevents and treats EEMyc lymphoma by restoring oncogene-induced senescence. <i>Cancer Discovery</i> , 2013 , 3, 82-95	24.4	52
141	The effect of temperature on the binding kinetics and equilibrium constants of monoclonal antibodies to cell surface antigens. <i>Molecular Immunology</i> , 1990 , 27, 327-33	4.3	52
140	SnapShot: Extrinsic apoptosis pathways. <i>Cell</i> , 2010 , 143, 1192, 1192.e1-2	56.2	51
139	Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell population. <i>Blood</i> , 2017 , 129, 2882-2895	2.2	49
138	PIDDosome-independent tumor suppression by Caspase-2. <i>Cell Death and Differentiation</i> , 2012 , 19, 1722-1727	1.37	49
137	Isotypic variants of the interferon-inducible transcriptional repressor IFI 16 arise through differential mRNA splicing. <i>Biochemistry</i> , 1998 , 37, 11924-31	3.2	48
136	Natural Killer Cells Suppress T Cell-Associated Tumor Immune Evasion. <i>Cell Reports</i> , 2019 , 28, 2784-2794.e5	1.56	46
135	Growth differentiating factor 15 enhances the tumor-initiating and self-renewal potential of multiple myeloma cells. <i>Blood</i> , 2014 , 123, 725-33	2.2	46
134	Deciphering the molecular events necessary for synergistic tumor cell apoptosis mediated by the histone deacetylase inhibitor vorinostat and the BH3 mimetic ABT-737. <i>Cancer Research</i> , 2011 , 71, 3603-15	10.1	46
133	A community-based model of rapid autopsy in end-stage cancer patients. <i>Nature Biotechnology</i> , 2016 , 34, 1010-1014	44.5	46
132	Epigenetic control of mitochondrial cell death through PACS1-mediated regulation of BAX/BAK oligomerization. <i>Cell Death and Differentiation</i> , 2017 , 24, 961-970	12.7	45
131	E6AP ubiquitin ligase regulates PML-induced senescence in Myc-driven lymphomagenesis. <i>Blood</i> , 2012 , 120, 822-32	2.2	45
130	A novel c-Jun-dependent signal transduction pathway necessary for the transcriptional activation of interferon gamma response genes. <i>Journal of Biological Chemistry</i> , 2007 , 282, 938-46	5.4	44
129	Role of TNF in lymphocyte-mediated cytotoxicity. <i>Microscopy Research and Technique</i> , 2000 , 50, 196-208	2.8	44
128	Mapping of the human PAWR (par-4) gene to chromosome 12q21. <i>Genomics</i> , 1998 , 53, 241-3	4.3	44
127	Imprinted CDKN1C is a tumor suppressor in rhabdoid tumor and activated by restoration of SMARCB1 and histone deacetylase inhibitors. <i>PLoS ONE</i> , 2009 , 4, e4482	3.7	44

126	Molecular and biologic analysis of histone deacetylase inhibitors with diverse specificities. <i>Molecular Cancer Therapeutics</i> , 2013 , 12, 2709-21	6.1	42
125	The role of p21(waf1/cip1) and p27(Kip1) in HDACi-mediated tumor cell death and cell cycle arrest in the Eμmyc model of B-cell lymphoma. <i>Oncogene</i> , 2014 , 33, 5415-23	9.2	40
124	Antibodies targeted to TRAIL receptor-2 and ErbB-2 synergize in vivo and induce an antitumor immune response. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008 , 105, 16254-9	11.5	40
123	Novel properties of the protein kinase CK2-site-regulated nuclear-localization sequence of the interferon-induced nuclear factor IFI 16. <i>Biochemical Journal</i> , 2001 , 353, 69-77	3.8	40
122	Histone-deacetylase inhibitors for the treatment of cancer. <i>Cell Cycle</i> , 2004 , 3, 779-88	4.7	40
121	BET Inhibition Induces Apoptosis in Aggressive B-Cell Lymphoma via Epigenetic Regulation of BCL-2 Family Members. <i>Molecular Cancer Therapeutics</i> , 2016 , 15, 2030-41	6.1	39
120	Different membrane cofactor protein (CD46) isoforms protect transfected cells against antibody and complement mediated lysis. <i>Transplant Immunology</i> , 1993 , 1, 101-8	1.7	39
119	Functional-genetic dissection of HDAC dependencies in mouse lymphoid and myeloid malignancies. <i>Blood</i> , 2015 , 126, 2392-403	2.2	38
118	Human astrocytes express membrane cofactor protein (CD46), a regulator of complement activation. <i>Journal of Neuroimmunology</i> , 1992 , 36, 199-208	3.5	37
117	Perforin-mediated suppression of B-cell lymphoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009 , 106, 2723-8	11.5	36
116	Translation inhibitors induce cell death by multiple mechanisms and Mcl-1 reduction is only a minor contributor. <i>Cell Death and Disease</i> , 2012 , 3, e409	9.8	36
115	Biochemical and growth regulatory activities of the HIN-200 family member and putative tumor suppressor protein, AIM2. <i>Biochemical and Biophysical Research Communications</i> , 2005 , 326, 417-24	3.4	36
114	CDK13 cooperates with CDK12 to control global RNA polymerase II processivity. <i>Science Advances</i> , 2020 , 6,	14.3	35
113	A focus on the preclinical development and clinical status of the histone deacetylase inhibitor, romidepsin (depsipeptide, Istodax(®)). <i>Epigenomics</i> , 2012 , 4, 571-89	4.4	35
112	Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents. <i>Expert Review of Anticancer Therapy</i> , 2007 , 7, 1439-49	3.5	35
111	Histone deacetylase inhibitors potently repress CXCR4 chemokine receptor expression and function in acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2002 , 119, 965-9	4.5	35
110	Blocking granule-mediated death by primary human NK cells requires both protection of mitochondria and inhibition of caspase activity. <i>Cell Death and Differentiation</i> , 2008 , 15, 708-17	12.7	33
109	Antagonism of IAPs Enhances CAR T-cell Efficacy. <i>Cancer Immunology Research</i> , 2019 , 7, 183-192	12.5	33

108	Interconversion between Tumorigenic and Differentiated States in Acute Myeloid Leukemia. <i>Cell Stem Cell</i> , 2019 , 25, 258-272.e9	18	32
107	The IFN-inducible nucleoprotein IFI 16 is expressed in cells of the monocyte lineage, but is rapidly and markedly down-regulated in other myeloid precursor populations. <i>Journal of Leukocyte Biology</i> , 1998 , 64, 546-54	6.5	31
106	A novel CDK9 inhibitor increases the efficacy of venetoclax (ABT-199) in multiple models of hematologic malignancies. <i>Leukemia</i> , 2020 , 34, 1646-1657	10.7	31
105	Multiple deficiencies underlie NK cell inactivity in lymphotoxin-alpha gene-targeted mice. <i>Journal of Immunology</i> , 1999 , 163, 1350-3	5.3	31
104	Functional analysis of the leukemia protein ELL: evidence for a role in the regulation of cell growth and survival. <i>Molecular and Cellular Biology</i> , 2001 , 21, 1672-81	4.8	30
103	Preclinical screening of histone deacetylase inhibitors combined with ABT-737, rhTRAIL/MD5-1 or 5-azacytidine using syngeneic Vk*MYC multiple myeloma. <i>Cell Death and Disease</i> , 2013 , 4, e798	9.8	29
102	Bcor loss perturbs myeloid differentiation and promotes leukaemogenesis. <i>Nature Communications</i> , 2019 , 10, 1347	17.4	25
101	Therapeutic Response to Non-genotoxic Activation of p53 by Nutlin3a Is Driven by PUMA-Mediated Apoptosis in Lymphoma Cells. <i>Cell Reports</i> , 2016 , 14, 1858-66	10.6	25
100	From anecdote to targeted therapy: the curious case of thalidomide in multiple myeloma. <i>Cancer Cell</i> , 2014 , 25, 9-11	24.3	25
99	P-glycoprotein does not protect cells against cytolysis induced by pore-forming proteins. <i>Journal of Biological Chemistry</i> , 2001 , 276, 16667-73	5.4	25
98	The curative outcome of radioimmunotherapy in a mouse breast cancer model relies on mTOR signaling. <i>Radiation Research</i> , 2014 , 182, 219-29	3.1	24
97	The drug vehicle and solvent N-methylpyrrolidone is an immunomodulator and antimyeloma compound. <i>Cell Reports</i> , 2014 , 7, 1009-19	10.6	24
96	CD271 Expression on Patient Melanoma Cells Is Unstable and Unlinked to Tumorigenicity. <i>Cancer Research</i> , 2016 , 76, 3965-77	10.1	23
95	Serglycin determines secretory granule repertoire and regulates natural killer cell and cytotoxic T lymphocyte cytotoxicity. <i>FEBS Journal</i> , 2016 , 283, 947-61	5.7	23
94	Genomic characterisation of EMyC mouse lymphomas identifies Bcor as a Myc co-operative tumour-suppressor gene. <i>Nature Communications</i> , 2017 , 8, 14581	17.4	22
93	Critical role of the transcription factor AP-1 for the constitutive and interferon-induced expression of IFI 16. <i>Journal of Cellular Biochemistry</i> , 2003 , 89, 80-93	4.7	22
92	The SMAC mimetic, LCL-161, reduces survival in aggressive MYC-driven lymphoma while promoting susceptibility to endotoxin shock. <i>Oncogenesis</i> , 2016 , 5, e216	6.6	22
91	Strong associations between RFLP and protein polymorphisms for CD46. <i>Immunogenetics</i> , 1992 , 36, 79-85	21	21

90	Long term, continuous exposure to panobinostat induces terminal differentiation and long term survival in the TH-MYCN neuroblastoma mouse model. <i>International Journal of Cancer</i> , 2016 , 139, 194-204 ⁵	7.5	21
89	Identifying molecular targets mediating the anticancer activity of histone deacetylase inhibitors: a work in progress. <i>Current Cancer Drug Targets</i> , 2002 , 2, 337-53	2.8	20
88	The PP2A-Integrator-CDK9 axis fine-tunes transcription and can be targeted therapeutically in cancer. <i>Cell</i> , 2021 , 184, 3143-3162.e32	56.2	20
87	A pharmacogenomic approach validates AG-221 as an effective and on-target therapy in IDH2 mutant AML. <i>Leukemia</i> , 2017 , 31, 1466-1470	10.7	19
86	Promises and challenges of anticancer drugs that target the epigenome. <i>Epigenomics</i> , 2011 , 3, 547-65	4.4	19
85	IL-15 Preconditioning Augments CAR T Cell Responses to Checkpoint Blockade for Improved Treatment of Solid Tumors. <i>Molecular Therapy</i> , 2020 , 28, 2379-2393	11.7	19
84	Id2 represses E2A-mediated activation of IL-10 expression in T cells. <i>Blood</i> , 2014 , 123, 3420-8	2.2	18
83	Tumor localization by combinations of monoclonal antibodies in a new human colon carcinoma cell line (LIM1899). <i>Cancer Research</i> , 1990 , 50, 5225-30	10.1	18
82	Id2 and E Proteins Orchestrate the Initiation and Maintenance of MLL-Rearranged Acute Myeloid Leukemia. <i>Cancer Cell</i> , 2016 , 30, 59-74	24.3	18
81	Epigenetic targeting of Notch1-driven transcription using the HDACi panobinostat is a potential therapy against T-cell acute lymphoblastic leukemia. <i>Leukemia</i> , 2018 , 32, 237-241	10.7	17
80	JAK2 is dispensable for maintenance of JAK2 mutant B-cell acute lymphoblastic leukemias. <i>Genes and Development</i> , 2018 , 32, 849-864	12.6	17
79	Fas ligand-mediated lysis of self bystander targets by human papillomavirus-specific CD8+ cytotoxic T lymphocytes. <i>Journal of Virology</i> , 1998 , 72, 5948-54	6.6	17
78	HDAC3 activity is required for initiation of leukemogenesis in acute promyelocytic leukemia. <i>Leukemia</i> , 2017 , 31, 995-997	10.7	16
77	AKT signalling is required for ribosomal RNA synthesis and progression of EEMyc B-cell lymphoma in vivo. <i>FEBS Journal</i> , 2013 , 280, 5307-16	5.7	16
76	P-Glycoprotein Protects Leukemia Cells Against Caspase-Dependent, but not Caspase-Independent, Cell Death. <i>Blood</i> , 1999 , 93, 1075-1085	2.2	16
75	HDAC Inhibitor Panobinostat Engages Host Innate Immune Defenses to Promote the Tumoricidal Effects of Trastuzumab in HER2 Tumors. <i>Cancer Research</i> , 2017 , 77, 2594-2606	10.1	15
74	Granzyme B triggers a prolonged pressure to die in Bcl-2 overexpressing cells, defining a window of opportunity for effective treatment with ABT-737. <i>Cell Death and Disease</i> , 2012 , 3, e344	9.8	15
73	Comparison of in vitro cell binding characteristics of four monoclonal antibodies and their individual tumor localization properties in mice. <i>Cancer Research</i> , 1990 , 50, 4423-8	10.1	15

72	AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-x, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia. <i>Clinical Cancer Research</i> , 2020 , 26, 6535-6549	12.9	15
71	A functional genomics screen identifies PCAF and ADA3 as regulators of human granzyme B-mediated apoptosis and Bid cleavage. <i>Cell Death and Differentiation</i> , 2014 , 21, 748-60	12.7	13
70	Genome-wide functional genomic and transcriptomic analyses for genes regulating sensitivity to vorinostat. <i>Scientific Data</i> , 2014 , 1, 140017	8.2	13
69	MLL-aberrant leukemia: complete cytogenetic remission following treatment with a histone deacetylase inhibitor (HDACi). <i>Annals of Hematology</i> , 2011 , 90, 847-9	3	13
68	Equivalent death of P-glycoprotein expressing and nonexpressing cells induced by the protein kinase C inhibitor staurosporine. <i>Biochemical and Biophysical Research Communications</i> , 2000 , 276, 231-7 ³⁻⁴	3.4	13
67	Lethal giant larvae 1 tumour suppressor activity is not conserved in models of mammalian T and B cell leukaemia. <i>PLoS ONE</i> , 2014 , 9, e87376	3.7	13
66	SUGAR-seq enables simultaneous detection of glycans, epitopes, and the transcriptome in single cells. <i>Science Advances</i> , 2021 , 7,	14.3	13
65	Efficient CRISPR/Cas9 Gene Editing in Uncultured Naive Mouse T Cells for In Vivo Studies. <i>Journal of Immunology</i> , 2020 , 204, 2308-2315	5.3	12
64	Down-regulation of a pro-apoptotic pathway regulated by PCAF/ADA3 in early stage gastric cancer. <i>Cell Death and Disease</i> , 2018 , 9, 442	9.8	12
63	Combination anti-CD137 and anti-CD40 antibody therapy in murine myc-driven hematological cancers. <i>Leukemia Research</i> , 2014 , 38, 948-54	2.7	12
62	DOCK8 Drives Src-Dependent NK Cell Effector Function. <i>Journal of Immunology</i> , 2017 ,	5.3	12
61	The combination of histone deacetylase inhibitors with immune-stimulating antibodies has potent anti-cancer effects. <i>Onc Immunology</i> , 2012 , 1, 377-379	7.2	12
60	A role for P-glycoprotein in regulating cell growth and survival. <i>Clinical and Applied Immunology Reviews</i> , 2003 , 4, 31-47		12
59	Distinct and overlapping mechanisms of resistance to azacytidine and guadecitabine in acute myeloid leukemia. <i>Leukemia</i> , 2020 , 34, 3388-3392	10.7	12
58	Targeting histone acetylation dynamics and oncogenic transcription by catalytic P300/CBP inhibition. <i>Molecular Cell</i> , 2021 , 81, 2183-2200.e13	17.6	12
57	CDK4/6 Inhibition Promotes Antitumor Immunity through the Induction of T-cell Memory. <i>Cancer Discovery</i> , 2021 , 11, 2582-2601	24.4	12
56	Inducible activation of IFI 16 results in suppression of telomerase activity, growth suppression and induction of cellular senescence. <i>Journal of Cellular Biochemistry</i> , 2010 , 109, 103-12	4.7	11
55	Serine Biosynthesis Is a Metabolic Vulnerability in FLT3-ITD-Driven Acute Myeloid Leukemia. <i>Cancer Discovery</i> , 2021 , 11, 1582-1599	24.4	11

54	Scribble acts as an oncogene in EMyc-driven lymphoma. <i>Oncogene</i> , 2016 , 35, 1193-7	9.2	10
53	A genome scale RNAi screen identifies GLI1 as a novel gene regulating vorinostat sensitivity. <i>Cell Death and Differentiation</i> , 2016 , 23, 1209-18	12.7	10
52	Durable clinical remission induced by romidepsin for chemotherapy-refractory peripheral T-cell lymphoma with central nervous system involvement. <i>Leukemia and Lymphoma</i> , 2017 , 58, 996-998	1.9	10
51	Enhancing the antitumor effects of radiotherapy with combinations of immunostimulatory antibodies. <i>Onc Immunology</i> , 2012 , 1, 1629-1631	7.2	10
50	Response: Does Bid Play a Role in the DNA Damage Response?. <i>Cell</i> , 2007 , 130, 10-11	56.2	10
49	Functional characterisation of alternatively spliced CD46 cytoplasmic tails. <i>Transplantation Proceedings</i> , 1992 , 24, 2329-30	1.1	10
48	Modulation of antitumour immune responses by intratumoural Stat1 expression. <i>Immunology and Cell Biology</i> , 2013 , 91, 556-67	5	9
47	Induction of autophagy does not alter the anti-tumor effects of HDAC inhibitors. <i>Cell Death and Disease</i> , 2012 , 3, e387	9.8	9
46	Antitumor activities and on-target toxicities mediated by a TRAIL receptor agonist following cotreatment with panobinostat. <i>International Journal of Cancer</i> , 2011 , 128, 2735-47	7.5	9
45	Regulating the TRAIL of destruction: how A20 protects glioblastomas from TRAIL-mediated death. <i>Cancer Discovery</i> , 2012 , 2, 112-4	24.4	9
44	The role of p202 in regulating hematopoietic cell proliferation and differentiation. <i>Journal of Interferon and Cytokine Research</i> , 2008 , 28, 5-11	3.5	9
43	Identification of four different CD46 (MCP) molecules with anti-peptide antibodies. <i>Biochemical and Biophysical Research Communications</i> , 1991 , 180, 1091-7	3.4	9
42	Targeting transcription cycles in cancer. <i>Nature Reviews Cancer</i> , 2021 ,	31.3	9
41	Commentary on: Biomarkers Provide Clues to Early Events in the Pathogenesis of Breast Implant-Associated Anaplastic Large Cell Lymphoma. <i>Aesthetic Surgery Journal</i> , 2016 , 36, 782-3	2.4	9
40	Combining the differentiating effect of panobinostat with the apoptotic effect of arsenic trioxide leads to significant survival benefit in a model of t(8;21) acute myeloid leukemia. <i>Clinical Epigenetics</i> , 2015 , 7, 2	7.7	8
39	Histone deacetylase inhibitors reduce glycoprotein VI expression and platelet responses to collagen related peptide. <i>Thrombosis Research</i> , 2013 , 131, 514-20	8.2	8
38	Rational combination therapies targeting survival signaling in aggressive B-cell leukemia/lymphoma. <i>Current Opinion in Hematology</i> , 2014 , 21, 297-308	3.3	8
37	Deamidation of Bcl-X(L): a new twist in a genotoxic murder mystery. <i>Molecular Cell</i> , 2002 , 10, 695-7	17.6	8

36	A role for multiple chimeric antigen receptor-expressing leukocytes in antigen-specific responses to cancer. <i>Oncotarget</i> , 2016 , 7, 34582-98	3.3	8
35	Regulatory T Cells Shape the Differential Impact of Radiation Dose-Fractionation Schedules on Host Innate and Adaptive Antitumor Immune Defenses. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021 , 111, 502-514	4	8
34	Novel properties of the protein kinase CK2-site-regulated nuclear-localization sequence of the interferon-induced nuclear factor IFI 16. <i>Biochemical Journal</i> , 2000 , 353, 69	3.8	7
33	Overview of Histone Deacetylase Inhibitors in Haematological Malignancies. <i>Pharmaceuticals</i> , 2010 , 3, 2674-2688	5.2	6
32	Cloning and characterisation of Ifi206: a new murine HIN-200 family member. <i>Journal of Cellular Biochemistry</i> , 2008 , 103, 1270-82	4.7	6
31	The multidrug resistance gene <i>mdr1a</i> influences resistance to ectromelia virus infection by mechanisms other than conventional immunity. <i>Immunology and Cell Biology</i> , 2004 , 82, 462-70	5	6
30	Coordinate functions of multiple complement regulating molecules, CD46, CD55, and CD59. <i>Transplantation Proceedings</i> , 1994 , 26, 1070-1	1.1	6
29	Tissue-specific expression of CD46 isoforms. <i>Transplantation Proceedings</i> , 1992 , 24, 2331-2	1.1	4
28	CD46 (MCP) confers protection from lysis by xenogeneic antibodies. <i>Transplantation Proceedings</i> , 1993 , 25, 396-7	1.1	4
27	Antigen-driven EGR2 expression is required for exhausted CD8 T cell stability and maintenance. <i>Nature Communications</i> , 2021 , 12, 2782	17.4	4
26	Targeting Bfl-1 via acute CDK9 inhibition overcomes intrinsic BH3-mimetic resistance in lymphomas. <i>Blood</i> , 2021 , 137, 2947-2957	2.2	4
25	A Histone Deacetylase Inhibitor, Panobinostat, Enhances Chimeric Antigen Receptor T-cell Antitumor Effect Against Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2021 , 27, 6222-6234	12.9	4
24	A Comprehensive Protocol Resource for Performing Pooled shRNA and CRISPR Screens. <i>Methods in Molecular Biology</i> , 2018 , 1725, 201-227	1.4	3
23	Dissecting the apoptotic mechanisms of chemotherapeutic drugs and lymphocytes to design effective anticancer therapies. <i>Drug Development Research</i> , 2001 , 52, 549-557	5.1	3
22	Molecular characterization of the polymorphic expression of CD46: a cell surface molecule protecting cells from complement attack. <i>Transplantation Proceedings</i> , 1992 , 24, 211-3	1.1	3
21	Constitutive IFN γ signaling maintains expression of signaling intermediaries for efficient cytokine responses. <i>Jak-stat</i> , 2016 , 5, e1173804		2
20	Histone deacetylase inhibitors are unable to synergize with ABT-737 in killing primary chronic lymphocytic leukaemia cells in vitro. <i>Leukemia</i> , 2012 , 26, 1433-5	10.7	2
19	HMBA induces activation of a caspase-independent cell death pathway to overcome P-glycoprotein-mediated multidrug resistance. <i>Blood</i> , 2000 , 95, 2378-2385	2.2	2

18	Temporal Analysis of Brd4 Displacement in the Control of B Cell Survival, Proliferation, and Differentiation. <i>Cell Reports</i> , 2020 , 33, 108290	10.6	2
17	MLL-TFE3: a novel and aggressive KMT2A fusion identified in infant leukemia. <i>Blood Advances</i> , 2020 , 4, 4918-4923	7.8	2
16	Suberanilohydroxamic Acid. Aton Pharma. <i>IDrugs: the Investigational Drugs Journal</i> , 2004 , 7, 674-82		2
15	Letter to the Editor, "BET inhibitor JQ1 blocks inflammation and bone destruction". <i>Journal of Dental Research</i> , 2015 , 94, 229	8.1	1
14	Structural organization, tissue expression, and chromosomal localization of Ciao 1, a functional modulator of the Wilms Tumor suppressor, WT1. <i>Immunogenetics</i> , 1999 , 49, 900-905	3.2	1
13	Whole genome CRISPR screening identifies TOP2B as a potential target for IMiD sensitization in multiple myeloma. <i>Haematologica</i> , 2021 , 106, 2013-2017	6.6	1
12	Reprogramming of serine metabolism is an actionable vulnerability in FLT3-ITD driven acute myeloid leukaemia		1
11	A PP2A-Integrator complex fine-tunes transcription by opposing CDK9		1
10	In the Midst of Life-Cell Death: What Is It, What Is It Good for, and How to Study It. <i>Cold Spring Harbor Protocols</i> , 2016 , 2016,	1.2	1
9	Epigenetic activation of plasmacytoid DC drives IFNAR-dependent therapeutic differentiation of AML.. <i>Cancer Discovery</i> , 2022 ,	24.4	1
8	Dual Targeting of Chromatin Stability By The Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Shows Significant Preclinical Efficacy in Neuroblastoma. <i>Clinical Cancer Research</i> , 2021 , 27, 4338-4352	12.9	0
7	Inhibition of pyrimidine biosynthesis targets protein translation in acute myeloid leukemia.. <i>EMBO Molecular Medicine</i> , 2022 , e15203	12	0
6	Joseph F. Sambrook (1939-2019). <i>Nature Structural and Molecular Biology</i> , 2019 , 26, 846-847	17.6	
5	The question begs--what is the role of P-glycoprotein in normal physiology?. <i>Drug Resistance Updates</i> , 1998 , 1, 340-2	23.2	
4	P-glycoprotein as a General Antiapoptotic Protein 2002 , 433-441		
3	Wilms Tumor Suppressor WT1 2002 , 543-551		
2	Growth Suppressors IFI-204 and IFI-205 Inhibit Primitive Hematopoietic Cell Proliferation In Vitro and in Vivo.. <i>Blood</i> , 2004 , 104, 1691-1691	2.2	
1	Epigenetic Drugs 2008 , 49-71		

